9/1011 sources · 8 publishersUpdated Oct 9, 04:11 UTC
Ultragenyx agrees to sell priority review voucher for $210 million
Ultragenyx Pharmaceutical entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million. The company received the voucher after the FDA approved Genglycos for glycogen storage disease type Ia. Completion remains contingent on customary conditions, including the Hart-Scott-Rodino waiting period.
Why it matters
Ultragenyx says the transaction would provide non-dilutive funding for its rare-disease pipeline and aid its progress toward profitability. The cash payment is not yet assured because the agreement has not closed.
Key facts
- 1Ultragenyx announced the definitive voucher-sale agreement on October 7, 2026. biopharminternational.com
- 2The agreed consideration is $210 million. globenewswire.com
- 3The voucher resulted from FDA approval of GENGLYCOS, also called DTX401, for glycogen storage disease type Ia. globenewswire.com
- 4Closing requires customary conditions, including expiry of the applicable Hart-Scott-Rodino Antitrust Improvements Act waiting period. globenewswire.com
- 5Ultragenyx did not disclose the buyer or a planned closing date. mugglehead.com
- 6Jefferies LLC is the exclusive financial adviser, while Gibson, Dunn and Crutcher LLP is legal counsel to Ultragenyx. globenewswire.com
Open questions
- Material 3 says 20% of the proceeds will go to NIH, but the company announcement does not state this; material 6 attributes a 20 per cent NIH payment to a separate Cyprium Therapeutics transaction.
- The purchaser and expected closing date have not been disclosed.
- The transaction remains subject to closing conditions and may not be completed.
Summary written by AlphAI from 10 of 11 sources. Not investment advice. Figures are as stated by the linked sources.